Terms: = Skin cancer AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS AND Treatment
176 results:
1. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract] [Full Text] [Related]
2. Analyses of tertiary lymphoid structures observed in cases of Merkel cell carcinoma showing spontaneous regression.
Nakamura M; Yoshimitsu M; Magara T; Kano S; Kato H; Morita A
Exp Dermatol; 2024 Mar; 33(3):e15062. PubMed ID: 38532566
[TBL] [Abstract] [Full Text] [Related]
3. Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?
Padonou F; Vanhulst T; Langouo-Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):63-68. PubMed ID: 38441065
[TBL] [Abstract] [Full Text] [Related]
4. PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagy-dependent melanoma.
Roy A; Chakraborty AR; DePamphilis ML
Mol Oncol; 2024 Apr; 18(4):988-1011. PubMed ID: 38414326
[TBL] [Abstract] [Full Text] [Related]
5. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
7. Secondary malignancies among mantle cell lymphoma patients.
Abalo KD; Smedby KE; Ekberg S; Eloranta S; Pahnke S; Albertsson-Lindblad A; Jerkeman M; Glimelius I
Eur J Cancer; 2023 Dec; 195():113403. PubMed ID: 37952281
[TBL] [Abstract] [Full Text] [Related]
8. Sono-activated materials for enhancing focused ultrasound ablation: Design and application in biomedicine.
Liao M; Du J; Chen L; Huang J; Yang R; Bao W; Zeng K; Wang W; Aphan BC; Wu Z; Ma L; Lu Q
Acta Biomater; 2024 Jan; 173():36-50. PubMed ID: 37939816
[TBL] [Abstract] [Full Text] [Related]
9. Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of chop plus auto-HSCT.
Zhang N; Zhang S; Ma L; Qiu L; Meng QL; Cai J; Xu Z; Yao H; Fan FY
Medicine (Baltimore); 2023 Oct; 102(40):e35413. PubMed ID: 37800816
[TBL] [Abstract] [Full Text] [Related]
10. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract] [Full Text] [Related]
11. Shikonin Causes Non-apoptotic Cell Death in B16F10 Melanoma.
Ahmad H; Crotts MS; Jacobs JC; Baer RW; Cox JL
Anticancer Agents Med Chem; 2023; 23(16):1880-1887. PubMed ID: 37393553
[TBL] [Abstract] [Full Text] [Related]
12. Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.
Sah VR; Jespersen H; Karlsson J; Nilsson LM; Bergqvist M; Johansson I; Carneiro A; Helgadottir H; Levin M; Ullenhag G; Ståhlberg A; Olofsson Bagge R; Nilsson JA; Ny L
Cancer Res Commun; 2023 May; 3(5):884-895. PubMed ID: 37377898
[TBL] [Abstract] [Full Text] [Related]
13. BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting.
Sorbi C; Belluti S; Atene CG; Marocchi F; Linciano P; Roy N; Paradiso E; Casarini L; Ronsisvalle S; Zanocco-Marani T; Brasili L; Lanfrancone L; Imbriano C; Di Rocco G; Franchini S
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298633
[TBL] [Abstract] [Full Text] [Related]
14. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract] [Full Text] [Related]
15. Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Ng KW; Boumelha J; Enfield KSS; Almagro J; Cha H; Pich O; Karasaki T; Moore DA; Salgado R; Sivakumar M; Young G; Molina-Arcas M; de Carné Trécesson S; Anastasiou P; Fendler A; Au L; Shepherd STC; Martínez-Ruiz C; Puttick C; Black JRM; Watkins TBK; Kim H; Shim S; Faulkner N; Attig J; Veeriah S; Magno N; Ward S; Frankell AM; Al Bakir M; Lim EL; Hill MS; Wilson GA; Cook DE; Birkbak NJ; Behrens A; Yousaf N; Popat S; Hackshaw A; ; ; Hiley CT; Litchfield K; McGranahan N; Jamal-Hanjani M; Larkin J; Lee SH; Turajlic S; Swanton C; Downward J; Kassiotis G
Nature; 2023 Apr; 616(7957):563-573. PubMed ID: 37046094
[TBL] [Abstract] [Full Text] [Related]
16. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
Cybulska-Stopa B; Piejko K; Ostaszewski K; Dziura R; Galus Ł; Ziółkowska B; Kempa-Kamińska N; Ziętek M; Bal W; Kamycka A; Dudzisz-Śledź M; Kubiatowski T; Kamińska-Winciorek G; Suwiński R; Mackiewicz J; Czarnecka AM; Rutkowski P
Melanoma Res; 2023 Jun; 33(3):208-217. PubMed ID: 37015054
[TBL] [Abstract] [Full Text] [Related]
17. Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma.
Deng J; Mi L; Wang X; Zhu J; Zhang C; Song Y
Hematology; 2022 Dec; 27(1):1272-1281. PubMed ID: 36476227
[TBL] [Abstract] [Full Text] [Related]
18. Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection.
Grześk E; Kołtan S; Dąbrowska A; Urbańczyk A; Małdyk J; Małkowski B; Bogiel T; Dębski R; Czyżewski K; Wysocki M; Styczyński J
Front Immunol; 2022; 13():915986. PubMed ID: 35990691
[TBL] [Abstract] [Full Text] [Related]
19. Synergistic antitumor effect of a penicillin derivative combined with thapsigargin in melanoma cells.
Bellizzi Y; Cornier PG; Delpiccolo CML; Mata EG; Blank V; Roguin LP
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3361-3373. PubMed ID: 35751681
[TBL] [Abstract] [Full Text] [Related]
20. DNA polymerase eta protects human cells against DNA damage induced by the tumor chemotherapeutic temozolomide.
Latancia MT; Moreno NC; Leandro GS; Ribeiro VC; de Souza I; Vieira WKM; Bastos AU; Hoch NC; Rocha CRR; Menck CFM
Mutat Res Genet Toxicol Environ Mutagen; 2022 Jun; 878():503498. PubMed ID: 35649682
[TBL] [Abstract] [Full Text] [Related]
[Next]
